Bone weakening diabetes drug

Beleaguered diabetes drug Avandia (Rosiglitazone, manufactured by GlaxoSmithKline) has now been linked to a significant intereference with new bone formation.
The drug, which has been commonly prescribed to people with type 2 diabetes for many years, was linked to weakened bones in a study of mice . Scientists in California, writing in journal Nature Medicine, condemned that drug buy also said that the effect could open up new treatment pathways to help those suffering from osteoporosis.
The fresh research was conducted at the Salk Institute in La Jolla, California . The research team reportedly wrote: “These findings have potential clinical implications, as they suggest that long-term rosiglitazone usage in the treatment of type 2 diabetes and insulin resistance may cause osteoporosis, owing to a combination of decreased bone formation and increased bone resorption.”
An expert from Diabetes UK reportedly said: “These findings are interesting. We already know that bone fractures are more common in people with diabetes taking rosiglitazones. This research could help us to understand better the effect the drug may have on bone health . However, a lot more research is needed before we can conclusively link rosiglitazones to increased risk of various bone conditions in humans.”

To Top